9803766-6
Pos copy

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07D 209/34, 207/38, 211/86, 207/26, 211/76, A61K 31/40, 31/445 — A1

(11) International Publication Number: WO 97/36867

(43) International Publication Date: 9 October 1997 (09.10.97)

(21) International Application Number: PCT/IB97/00076

(22) International Filing Date: 3 February 1997 (03.02.97)

(30) Priority Data:
60/015,134 29 March 1996 (29.03.96) US

(71) Applicant *(for all designated States except US)*: PFIZER INC. [US/US]; 235 Est 42nd Street, New York, NY 10017 (US).

See Form PCT add

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: HOWARD, Harry, R. [US/US]; 272 Westwoods Terrace, Bristol, CT 06010 (US).

(74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).


(81) Designated States: AU, BG, BR, CA, CN, CZ, HU, IL, IS, JP, KR, LK, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, US, UZ, VN, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.


(54) Title: BENZYL(IDENE)-LACTAM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE (ANT)AGONISTS OF 5-HT1A- AND/OR 5-HT1D RECEPTORS

(57) Abstract


A compound of formula (I) wherein R^1 is a group of formula G^1, G^2, G^3, G^4 or G^5; R^2 is hydrogen, (C_1-C_4)alkyl, phenyl or naphthyl, wherein said phenyl or naphthyl may optionally be substituted with one or more substituents, preferably from zero to three substituents, independently selected from chloro, fluoro, bromo, iodo, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, trifluoromethyl, cyano and SO_g(C_1-C_6)alkyl wherein g is zero, one or two; R^3 is $(CH_2)_m$B, wherein m is zero, one, two or three and B is hydrogen, phenyl, naphthyl or a 5- or 6-membered heteroaryl group containing from one to four hetero atoms in the ring (e.g., furyl, thienyl, pyridyl, pyrimidyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, etc.), and wherein each of the foregoing aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably from zero to three substituents, independently selected from chloro, fluoro, bromo, iodo, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, trifluoromethyl, cyano hydroxy, COOH and SO_g(C_1-C_6)alkyl, wherein g is zero, one or two; Z is CR^4R^5, wherein R^4 and R^5 are independently selected from hydrogen, (C_1-C_6)alkyl and trifluoromethyl; or Z may be one of the aryl or heteroaryl groups referred to in the definition of B above and wherein two adjacent ring members of Z are also members of ring A; X is hydrogen, chloro, fluoro, bromo, iodo, cyano, (C_1-C_5)alkyl, hydroxy, trifluoromethyl, (C_1-C_6)alkoxy, -SO_g(C_1-C_6)alkyl, wherein g is zero one or two, CO_2R^{10} or $CONR^{11}R^{12}$; each of R^{10}, R^{11} and R^{12} is selected, independently, from the radicals set forth in the definition of R^2; or R^{11} and R^{12}, together with the nitrogen to which they are attached, form a 5- to 7-membered ring that may contain from zero to four heteroatoms selected from nitrogen, sulfur and oxygen; n is one, two, three or four; and the broken line indicates an optional double bond; and R^6, R^7, R^8, R^9, R^{13}, E, p and x are defined as in the specification; with the proviso that n must be one when Z is a heteroaryl group; or a pharmaceutically acceptable salt thereof. These compounds are selective (ant)agonists of 5-HT_{1A}- and/or 5-HT_{1D} receptors and thus are useful as psychotherapeutic agents.



(I)



(G^1) (G^2) (G^3)



(G^4) OR (G^5)